Page 2 - Tourmaline Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Sandeep kulkarniSarah mishekDrug administrationExchange commissionDevelopment expensesTourmaline bio incBio reports first quarterRecent businessInitiated phaseInvestigational new drugAtherosclerotic cardiovascular diseaseExpanded thyroid eye diseaseChief executive officerUpcoming milestonesCorporate highlightsTourmaline bio

TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024

TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Tourmaline bioPlace earnings

Vivo Capital LLC Purchases Shares of 591,882 Tourmaline Bio, Inc (NASDAQ:TRML)

Vivo Capital LLC Purchases Shares of 591,882 Tourmaline Bio, Inc (NASDAQ:TRML)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Jefferies financial groupTourmaline bio incVivo capitalCapital managementSecurities exchange commissionTourmaline bioFree reportGet free reportVisit holdingschannelTourmaline bio daily

Tourmaline Bio, Inc (NASDAQ:TRML) Receives Average Rating of Buy from Brokerages

Tourmaline Bio, Inc (NASDAQ:TRML) Receives Average Rating of Buy from Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Mark mcdadeCapital managementTourmaline bio incDenali advisorsAffinity asset advisorsJump financialSecurities exchange commissionJefferies financial groupTourmaline bioGet free reportFinancial groupDirector mark mcdadeExchange commissionAsset advisorsGet freeTourmaline bio daily

Tourmaline Bio, Inc (NASDAQ:TRML) Given Average Rating of Buy by Analysts

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last […]

Mark mcdadeJefferies financial groupCapital managementDenali advisorsAffinity asset advisorsTourmaline bio incJump financialTourmaline bioGet free reportFinancial groupTruist financialDirector mark mcdadeAsset advisorsGet freeTourmaline bio dailyNasdaq trml